

**6 Month Trial Sub-License for Gene Bridges' Red® /ET® Recombination  
to Commercial Organisation for Non-Commercial, Research Purposes**

Between

**Gene Bridges GmbH**, Im Neuenheimer Feld 584, 69120 Heidelberg, Germany

- "GENE BRIDGES" -

and

(name of commercial company)

- "LICENSEE" -

the following is agreed upon:

**PREAMBLE:**

GENE BRIDGES is owner of a license under particular patents and patent applications with the right to grant sub-licenses. LICENSEE desires to sublicense from GENE BRIDGES particular patent rights. GENE BRIDGES and LICENSEE agree to the following:

**ARTICLE 1**

**DEFINITIONS**

**1.1 Affiliate** shall mean with respect to a party:

Any entity directly or indirectly controlled by, controlling, or under common control with such party, where "control" means having the majority of the voting rights thereof.

**1.2 Class I Product** shall mean:

A DNA construct which is, or is intended to be, used to alter a mammalian cell so that said mammalian cell (i) carries a genetic modification resulting from the insertion of the said DNA construct targeted to a predetermined, specific chromosomal location without the intent to alter the function or expression of the gene(s) at the site of the targeted chromosomal location; and (ii) is or is intended to

be used to create a line of mammalian animals. For clarity, Class I Product includes the said DNA construct (the "**Class I Construct**"), the said altered mammalian cell and the said altered mammalian animal line. Class I Product only includes the insertion of DNA sequences that are not intended to (a) alter the function or expression of the gene(s) at the site of the targeted chromosomal location, or (b) have a phenotypic impact on the said altered mammalian animal line. Examples of DNA sequences which can be inserted in ways that would not alter the function or expression of the gene(s) at the site of the targeted chromosomal location and thus would be expected not to have a phenotypic impact, are those encoding reporter proteins such as GFP or lacZ cell surface markers, protein tags or transacting utility proteins, such as recombinases including Cre and FLP recombinases, but do not include libraries of cDNAs to be screened for phenotypic effects of their misexpression. For clarity, a Class I product is commonly known as "conditional knock-outs", "reporter strains", "cell-surface markers", "protein tagging", "transacting utility proteins" (such as Cre, Flp, or Fre Recombinase).

**1.3 Class II Product** shall mean:

A DNA construct which is used to, or is intended to, alter a mammalian cell so that said mammalian cell (i) carries a genetic modification resulting from the insertion of the said DNA construct targeted to a predetermined, specific chromosomal location with the intent to alter the function or expression of the gene(s) that was at, or is inserted into, the site of the targeted chromosomal location; and (ii) is or is intended to be used to create a line of mammalian animals. For clarity, Class II Product includes the said DNA construct (the "**Class II Construct**"), the said altered mammalian cell and the said altered mammalian animal cell line. Class II Product includes DNA constructs designed to delete all or part of a gene sequence or replace all or part of a gene sequence with a reporter, such as LacZ or GFP, as well as gain-of-function Class II Products whereby a DNA sequence is inserted into a predetermined, specific chromosomal location in a mammalian cell with the intention to test the phenotypic impact of the inserted DNA sequences on the said altered mammalian animal line. For examples, gain-of-function Class II Products include the insertion beside a chosen gene of another gene, the insertion of a dominant negative allele of a chosen gene, the insertion of a cDNA, or the insertion of any other gene with the intent to examine its phenotypic impact in the said altered mammalian animal line. For clarity, a Class II Product is commonly known as "receptor modification", "gain-of-function of a specific gene", "conventional knock-out" and "conventional knock-in".

**1.4 Diagnostic Procedure** shall mean:

A procedure related to the detection of chosen DNA or RNA sequences.

**1.5 Know-how** shall mean:

All information, know-how, experiences, or trade secrets pertaining to the use of the Licensed Technology which is necessary for LICENSEE to exercise the rights licensed hereunder, including but not limited to the specific information indicated in **Annex I**.

**1.6 Licensed Technology** shall mean:

Methods for generating Class I Constructs, Class II Constructs, Transgenic Constructs and Viral Engineering Constructs using the Red<sup>®</sup>/ET<sup>®</sup> Recombination Method covered by the Patent Rights.

**1.7 Metabolic Engineering** shall mean:

Cloning, shuffling and/or modification, in particular through cloning, subcloning, deletion, insertion and/or mutation, of genes, gene fragments or nucleic acids containing those genes whose products are involved in the synthesis pathways of secondary metabolites, in particular in the polyketide, non-ribosomal peptide synthase and fatty acid synthase pathways (the “**Metabolic Genes**”).

**1.8 Patent Rights** shall mean:

The rights of GENE BRIDGES in patents and patent applications PCT-Application WO 99/29837 claiming priority of the European Patent Application No. 97 121 462.2 (December 5, 1997) and 98 118 756.0 (October 5, 1998) and the PCT-Application WO 01/04288 claiming priority of U.S. Application no. 09/350,830 (filed July 9, 1999), which has issued as US patent number 6,355,412. indicated in **Annex III**.

**1.9 Person** shall mean:

Any natural person, corporation, general partnership, limited partnership, joint venture, proprietorship, organization, university, academic or research institution, or other business or not-for-profit entity.

**1.10 Recombinant Service** shall mean:

A service provided by LICENSEE to any Third Party, in which LICENSEE is provided financial benefits or any other con

sideration including but not limited to an acquisition of shares or rights or an exchange of materials or information in exchange for the alteration, generation, cloning or subcloning of any Research Product.

**1.11 Red<sup>®</sup>/ET<sup>®</sup> Recombination Method** shall mean:

A recombination method for specific modification of *E. coli* compatible DNA target molecules, by *in vivo* homologous recombination with a targeting DNA molecule in prokaryotic cells. The position at which the target molecules are modified is determined by the design of the targeting molecule with which the target molecule recombines. The method also encompasses direct cloning and subcloning

of target DNA sequences from various donor molecules. The method is described and claimed in further detail in the Patent Rights.

**1.12 Research Purpose** shall mean:

The use of the Licensed Technology in the research facilities of LICENSEE solely for a non-commercial research purposes of LICENSEE. "Commercial" in this context shall mean: any action procedure or service for a Third Party in exchange for financial benefits or any other consideration including but not limited to an acquisition of shares or rights or an exchange of materials or information.

**1.13 Third Party** shall mean:

A Person other than LICENSEE, GENE BRIDGES or an Affiliate.

**1.14 Transgenic** shall mean:

A DNA construct which is, or is intended to be, used to alter a mammalian cell so that said mammalian cell carries a genetic modification resulting from the insertion of the said DNA construct that is not targeted to a predetermined, specific chromosomal location with or without the intent to alter the function or expression of the gene(s) at the site of the chromosomal insertion. Said DNA construct may be used to create a line of mammalian animals. For clarity, Transgenic includes the said DNA construct (the "**Transgenic Construct**"), the said altered mammalian cell and the said altered mammalian animal line. Transgenic does not include Class I or Class II Products.

**1.15 Trial License Term** shall mean:

A period of 6 (six) months starting from the date of the last signature on this document.

**1.16 Viral Engineering Product** shall mean:

A DNA construct, which is used to clone, shuffle or modify DNA or pieces of DNA that are partially or completely leading, or are meant to lead to, the *in vivo* or *in vitro* production of a virus regardless of the replication competence or incompetence of said virus (the "**Viral Engineering Construct**"). Virus includes all viruses whose life cycle is dependent upon either single-stranded or double-stranded DNA or RNA. Said DNA construct may be used to create a cell line or a virus, however, Viral Engineering Constructs which also fall under the definition of Class I, II or Transgenic Constructs are not considered Viral Engineering Constructs with respect to the license grant.

**1.17 Year** shall mean:

The twelve-month calendar year starting on 1<sup>st</sup> January and ending on 31<sup>st</sup> December.

**ARTICLE 2****SUBLICENSE GRANT AND TRANSFER OF MATERIAL****2.1 Non-exclusive Research License for Class II Products**

Subject to the terms and conditions of this Agreement, GENE BRIDGES hereby grants LICENSEE the non-exclusive right to make and have made by its Affiliate up to 5 Class II Constructs under the Licensed Technology in the research facilities of its own or of its Affiliate (but not the facilities of any other Third Party - "**The Sublicense Limit**") within the Trial License Term and to use Class II Products generated there from for Research Purposes.

**2.2 Non-exclusive Research License for Class I Products**

GENE BRIDGES hereby grants LICENSEE the non-exclusive right to make and have made by its Affiliate up to 5 Class I Constructs under the Licensed Technology within the Trial License Term and to use Class I Products generated therefrom for Research Purposes.

**2.3 Non-exclusive Research License for Transgenics**

GENE BRIDGES hereby grants to LICENSEE the non-exclusive right to make and have made by its Affiliate up to 5 Transgenic Constructs under the Licensed Technology within the Trial License Term and to use Transgenic Construct generated therefrom for Research Purposes.

**2.4 Non-exclusive Research License for Viral Engineering Products**

GENE BRIDGES hereby grants to LICENSEE the non-exclusive right to make and have made by its Affiliate up to 5 Viral Engineering Constructs under the Licensed Technology within the Trial License Term and to use Viral Engineering Products generated therefrom for Research Purposes.

**2.5 Research Purpose; No Allowance for Sublicense Grant**

During the Trial License Term, LICENSEE shall in any case be entitled to use the Licensed Technology for non-commercial, internal Research Purposes. Any other use is considered to be outside the scope of the license granted under this Agreement. LICENSEE is in particular not entitled to any sublicense grant or to transfer or assign the licensed right(s). Furthermore, LICENSEE is in particular not entitled to use the Red/ET Recombination Method in a Diagnostic Procedure, in a Recombinant Service, or in Metabolic Engineering. For clarity the generation of Class I, II, Transgenic or Viral Engineering Constructs containing and/or targeting Metabolic Genes is considered Metabolic Engineering. The Licensee is not allowed to make improvements to the technology licensed from Gene Bridges.

**2.6 Field of Use Limitation**

The parties acknowledge that they are, within this Article 2, defining the field of use of the Patent Rights by the constructs, cells animals, viruses and plants that can be made and used for Research Purposes: provided, however, that it is the intention of the parties that LICENSEE may use any Class II Products, Class I products, Transgenics and Viral Engineering Products made by LICENSEE with the license granted hereunder for any purpose thereafter if the parties enter into a further commercial license agreement to the same Red<sup>®</sup>/ET<sup>®</sup> Recombination Method. For clarity, nothing in this Agreement shall be construed or deemed as creating any obligation of LICENSEE to enter into such license agreement or any further agreement with GENE BRIDGES.

## **2.8 Execution of a Certificate**

LICENSEE will execute a certificate attached hereto as **Annex III** at the end of the Trial License Term and deliver it to GENE BRIDGES no later than 4 weeks of the following month upon request from GENE BRIGES.

## **ARTICLE 3**

### **FINANCIAL CONSIDERATION**

#### **3.1 Consideration**

The consideration for the rights granted and the Material provided is Euros 3,500- (plus VAT tax where applicable). This amount is (together with VAT) due within thirty (30) days of signing this Agreement. Payments shall be made to GENE BRIDGES upon receipt of an appropriate invoice form GENE BRIDGES. Any and all additional costs, including shipment of Materials and written documents shall be borne by LICENSEE. ). Failure by LICENSEE to make timely payment within thirty (30) days of signing this Agreement will result in a surcharge fee of 4% of the amount overdue per calendar month.

#### **3.2 Excess of the Licensed Class II Constructs**

Should LICENSEE make more than the Sublicense Limit within the Trial License Term, an additional license fee of US\$ 100,000 per Class II Construct in excess of the Sublicense Limit shall be payable to GENE BRIDGES immediately following the Trial License Term. GENE BRIDGES shall have the right to assign its rights against LICENSEE to a Third Party for purposes of enforcing GENE BRIDGES' rights to claim the license fee and damages. Thus, the additional license fee becomes payable immediately following the Trial License Term in which LICENSEE makes more than the Sublicense Limit.

#### **3.3 Taxes**

All turnover taxes and indirect taxes shall be borne by LICENSEE.

## ARTICLE 4

### WARRANTIES AND INDEMNITIES

4.1 GENE BRIDGES does not assume liability for any damage occurring through the use by LICENSEE of the Licensed Technology or Material for any purpose, in particular arising out of the care, handling, disposal and breeding of the Material. GENE BRIDGES gives no warranty nor makes any representation, express or implied, with regards to the suitability of the Licensed Technology or Material for any applications or purposes of LICENSEE.

4.2 GENE BRIDGES warrants that to the best of its knowledge, it has been authorized to sub-license the Licensed Technology as provided for herein.

4.3 GENE BRIDGES represents and warrants as follows:

(a) this Agreement is and shall be a legal and valid obligation binding upon GENE BRIDGES, enforceable in accordance with its terms;

(b) the execution and delivery of this Agreement, does not and will not constitute a breach or violation of any other agreement or understanding, written or oral, to which it is a party; and

(c) the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of GENE BRIDGES, and the person executing this Agreement on behalf of GENE BRIDGES has been duly authorized to do so by all requisite corporate action.

4.4 LICENSEE represents and warrants as follows:

(a) this Agreement is and shall be a legal and valid obligation binding upon LICENSEE, enforceable in accordance with its terms;

(b) the execution and delivery of this Agreement, and the use of the Licensed Technology, do not and will not constitute a breach or violation of any other agreement or understanding, written or oral, to which it is a party;

(c) the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of LICENSEE, and the person executing this Agreement on behalf of LICENSEE has been duly authorized to do so by all requisite corporate action; and

(d) LICENSEE shall use the Licensed Technology in accordance with all applicable laws, rules and regulations.

4.5 GENE BRIDGES guarantees neither the patentability nor the validity of the Patent Rights, and shall not be liable accordingly.

4.6 LICENSEE agrees to comply with all applicable laws, rules and regulations relating to the care, welfare, handling, breeding, storage, transfer and disposal of Material, including laws relating to shipment to and from GENE BRIDGES.

## **ARTICLE 5 CONFIDENTIALITY**

5.1 Except as expressly contemplated by the license granted hereunder, LICENSEE shall not disclose or transfer, sell, distribute and/or exchange to any Third Party without prior consent of GENE BRIDGES any confidential or secret information or Know-how or trade secrets confided or made available by GENE BRIDGES (collectively "**Confidential Information**") in particular, (1) data or information of any kind, including Know-how, as well as (2) Material. Notwithstanding anything to the contrary herein, LICENSEE's obligations of confidentiality and non-use hereunder shall not apply to any information, Know-how or trade secrets that:

(a) is at the time of the disclosure by GENE BRIDGES in the possession of LICENSEE;

(b) is at the time of the disclosure by GENE BRIDGES available to the public;

(c) after the disclosure by GENE BRIDGES is published or becomes available to the public by the publication or otherwise, other than by an unauthorized act or omission by the LICENSEE; or,

(d) LICENSEE rightfully receives without any confidential obligations from any third party having the lawful right to make such disclosure.

5.2 LICENSEE may disclose Confidential Information pursuant to an order of a competent court or administrative agency, provided that it has informed GENE BRIDGES of such order, and has used reasonable efforts to limit the scope of the disclosure and to obtain confidential treatment by the court or administrative agency of the Confidential Information disclosed pursuant to such order.

5.3 This obligation of confidentiality shall survive expiration and/or termination of this Agreement or any part of it for a period of five (5) years from the time of disclosure of such CONFIDENTIAL INFORMATION. The obligations of confidentiality apply to LICENSEE and its Affiliate.

5.4 LICENSEE will cause its employees or Affiliate that uses the Red<sup>®</sup>/ET<sup>®</sup> Recombination Method, the Material or that have knowledge of Know How to be under non-disclosure obligations with respect thereto.

**ARTICLE 6****NO-CHALLENGE CLAUSE**

LICENSEE agrees not to challenge the patentability or validity of the Patent Rights during the duration of this Agreement and not to support, directly or indirectly, third parties in challenging the patentability or validity of the Patent Rights.

**ARTICLE 7****TERM AND TERMINATION**

As defined in Section 1.15 ("Trial License Term"), the license granted to LICENSEE shall expire upon 6 months after last signature on this agreement. Upon termination of the Trial License Term, LICENSEE will immediately cease to use the Licensed Technology.

**ARTICLE 8****GENERAL CONDITIONS****8.1 Amendments and Modifications**

Amendments and modifications to this Trial License Agreement including the amendment and modification of this provision may be made only in writing signed by both parties.

**8.2 Governing Law; Jurisdiction**

This Agreement shall be governed by and construed in accordance with the substantive laws of the Federal Republic of Germany, without reference to conflicts of law principles. The parties hereby unconditionally submit to the exclusive jurisdiction of the District Court Düsseldorf, Germany

**8.3 Assignment**

This Agreement may not be assigned by GENE BRIDGES or its successors in interest, assigns, trustees and other legal representatives without a prior written consent of the LICENSEE which shall not be unreasonably withheld.

**8.4 Waiver**

Any failure by a party to insist upon strict performance of any provision hereof, at anytime or for any period of time, shall not constitute a waiver of, or estoppel against asserting, the right to require such performance in the future. No waiver of any term or condition of this Agreement shall be effective unless set forth in a written instrument duly executed by or on behalf of the party waiving such term or condition.

### **8.5 Force Majeure**

Neither party shall be liable or deemed to be in breach of this agreement by reason of any delay in performing, or failure to perform, any of its obligations if the delay or failure was due to any cause beyond that party's control. Causes beyond a party's reasonable control include, but are not limited to, an act of God, explosion, flood, tempest, fire or accident, war or threat of war, sabotage, insurrection, civil disturbance or requisition, acts, restrictions, bye-laws, prohibitions, or measures of any kind on the part of any governmental, parliamentary or local authority, import or export regulations or embargoes, strikes, lock-outs or other industrial actions or trade disputes (whether involving employees of Gene Bridges, customer or a third party), difficulties in obtaining raw materials, materials from suppliers, labor, fuel parts or machinery, power failure, power surge or spike, telecommunications failure or breakdown of machinery.

### **8.6 Successors and Assigns**

This Agreement shall be binding upon, and inure to the benefit of, the parties, successors and permitted assigns.

### **8.7 Annexes**

All Annexes are part of this Agreement

LICENSEE

Name: \_\_\_\_\_ Signature: \_\_\_\_\_

Title: \_\_\_\_\_ Date: \_\_\_\_\_

GENE BRIDGES

Name: Gary Stevens

Signature: \_\_\_\_\_

Title: Chief Executive Officer

Date: \_\_\_\_\_

## **Annex I**

### **Know How**

- 1) Instruction and/or trouble-shooting guides and manuals
- 2) Training materials
- 3) Protocols
- 4) Any information, such as advice, strategy consultation, technical details, protocols, references and other know-how reduced to writing by GENE BRIDGES

Attachments:

Copies of the information indicated above

## Annex II

### Patent Rights

- I. Patent Application PCT/EP98/07945, Novel DNA Cloning Method (ET) Priority date December 5, 1997;
- II. U.S. Patent Application no. 09/350,830 filed July 9, 1999, Directed Cloning and Subcloning;
- III. Related know how and reagents complementary to the patent and patent applications listed in Exhibit B; and
- IV. US Patent nos. 6,355,412 and 6,509,156B by Stewart et.al. including the following related patents and applications:

<b>US 6509156 FAMILY</b>			
<b>Country</b>	<b>Title</b>	<b>Appln. No.</b>	<b>Filing Date</b>
Austria	Neue Methode Zur Klonierung Dns Unter Anwendung Des E. Coli Rece/Rect Rekombinationssysteme	AT19980963541T	12/07/98
Australia	Novel DNA Cloning Method	AU19990018771	12/07/98
Australia	Novel DNA Cloning Method	AU19990018771D	12/07/98
Canada	Novel DNA Cloning Method	CA19982312474	12/07/98
Germany	DNA Cloning Method Relying On The E. Coli Rece/Rect Recombination System	DE19986015384	12/07/98
Germany	DNA Cloning Method Relying On The E. Coli Rece/Rect Recombination System	DE19986015384T	12/07/98
Denmark	DNA Cloning Method Relying On The E. Coli Rece/Rect Recombination System	DK19980963541T	12/07/98
Europe	Novel DNA Cloning Method Relying On The E. Coli Rece/Rect Recombination System	EP19980963541	12/07/98
Europe	Novel DNA Cloning Method Relying On The E. Coli RECE/RECT Recombination System	EP20020021915	12/07/98
Spain	DNA Cloning Method Relying On The E. Coli Rece/Rect Recombination System	ES19980963541T	12/07/98
Japan	DNA Cloning Method Relying On The E. Coli RecE/RecT Recombination System	JP20000524410T	12/07/98
Portugal	Novo Metodo De Clonagem De Adn Baseado No Sistema De Recombinacao Rece/Rect De E. Coli	PT19980963541T	12/07/98
United States	DNA Cloning Method Relying On The E. Coli Rece/Rect Recombination System	US20000555510	06/05/00
United States	Novel DNA Cloning Method	US20020231013	08/30/02

<b>US 6509156 FAMILY</b>			
<b>Country</b>	<b>Title</b>	<b>Appln. No.</b>	<b>Filing Date</b>
United States	Novel DNA cloning method	US20040842534	05/11/04
PCT	Novel DNA Cloning Method	WO1998EP07945	12/07/98

<b>US 6355412 FAMILY</b>			
<b>Country</b>	<b>Title</b>	<b>Appln No.</b>	<b>Filing Date</b>
Australia	Methods And Compositions For Directed Cloning And Subcloning Using Homologous Recombination	AU20000066911	07/10/00
Australia	Methods And Compositions For Directed Cloning And Subcloning Using Homologous Recombination	AU20000066911D	07/10/00
Brazil*	Methods And Compositions For Directed Cloning And Subcloning Using Homologous Recombination	BR20000012283	07/10/00
Canada	Methods And Compositions For Directed Cloning And Subcloning Using Homologous Recombination	CA20002377938	07/10/00
China	Method And Compositions For Directed Cloning And Subcloning Using Homologous Recombination	CN20000812739	07/10/00
Europe	Methods And Compositions For Directed Cloning And Subcloning Using Homologous Recombination	EP20000954461	07/10/00
Israel	No English Title Available	IL147385D	Unavailable
Japan	Methods And Compositions For Directed Cloning And Subcloning Using Homologous Recombination	JP20010509492T	07/10/00
Mexico	Methods And Compositions For Directed Cloning And Subcloning Using Homologous Recombination	MX2002PA00233	07/10/00
Poland	Methods And Compositions For Directed Cloning And Subcloning Using Homologous Recombination	PL20000353634	07/10/00
United States	Methods And Compositions For Directed Cloning And Subcloning Using Homologous Recombination	US19990350830	07/09/99
PCT	Methods And Compositions For Directed Cloning And Subcloning Using Homologous Recombination	WO2000EP06533	07/10/00
South Africa	Methods And Compositions For Directed Cloning And Subcloning Using Homologous Recombination	ZA20020000152	01/08/02

## Annex III

[INSERT DATE]

Gene Bridges GmbH  
Im Neuenheimer Feld 584  
D-69120 Heidelberg, Germany

To Whom it May Concern:

[YOUR NAME] (“Company”) hereby certifies to Gene Bridges GmbH (“Gene Bridges”) that it, together with its AFFILIATES (as defined below), has not made under its sublicense more than 2 Class II Products (as defined below), less any Class II Products purchased or received from Gene Bridges during the Trial License Term (as defined below).

Class II Products shall mean: A DNA construct which is, or is intended to be, used to alter a mammalian cell so that said mammalian cell (i) carries a genetic modification resulting from the insertion of the said DNA construct targeted to a predetermined, specific chromosomal location with the intent to alter the function or expression of the gene(s) that was at, or is inserted into, the site of the targeted chromosomal location; and (ii) is, or is intended to be, used to create a line of mammalian animals. For clarity, Class II Product includes the said DNA construct, the said altered mammalian cell and the said altered mammalian animal cell line. Class II Products include DNA constructs designed to delete all or part of a gene sequence or replace all or part of a gene sequence with a reporter, such as LacZ or GFP, as well as gain-of-function Class II Products whereby a DNA sequence is inserted into a predetermined, specific chromosomal location in a mammalian cell with the intention to test the phenotypic impact of the inserted DNA sequences on the said altered mammalian animal line. For examples, gain-of-function Class II Products include the insertion beside a chosen gene of another gene, the insertion of a dominant negative allele of a chosen gene, the insertion of a cDNA, or the insertion of any other gene with the intent to examine its phenotypic impact in the said altered mammalian animal line.

AFFILIATE shall mean: Any entity directly or indirectly controlled by, controlling, or under common control with Company, where “control” means having the majority of the voting right thereof. The term “ownership” shall relate to equity interest (or an equivalent interest), partnership interest (or an equivalent interest), or voting interest.

For purposes of determining the number of Class II Products referred to above, all DNA constructs, cells or animals carrying the identical genetic alteration shall be counted as one (1) Class II Product. Company shall use the date of manufacture of the DNA construct or the date of receipt of the Class II Constructs, cells or animals from Gene Bridges, as the case may be, for purposes of determining the number of Class II Products that are made, purchased or received per Year. Any DNA construct that can be shown to have failed to result in a cell with the desired modification shall not be counted as part of the total number of allowed Class II Products.

Trial License Term shall mean: A period of 6 (six) months, starting with LICENSEE'S receipt of Material.

Sincerely,

[YOUR NAME]

---